• Skip to main content
  • Skip to primary sidebar
virology blog

virology blog

About viruses and viral disease

neuraminidase

When Two Different Viruses Have Offspring

5 January 2023 by Gertrud U. Rey 6 Comments

by Gertrud U. Rey

This image is for illustrative purposes only and does not reflect the exact geographical locations of the IAV and RSV genomes and glycoproteins in the HVPs.

Have you ever wondered what would happen if you were infected with two different viruses at the same time? A recent study aimed at addressing this question has produced some astounding new findings.

The authors of the study wanted to observe the interactions between respiratory syncytial virus (RSV) and influenza A virus (IAV), so they infected lung cells with either virus or a mixture of both viruses. An initial experiment comparing the replication kinetics of each virus in co-infected cells to those infected with either virus showed that co-infection had no impact on the replication of IAV, but did lead to reduced replication of RSV.  

IAV and RSV each localize to distinct cellular regions during their individual courses of infection – RSV aggregates in cytoplasmic complexes known as inclusion bodies, and IAV scatters more diffusely throughout the cytoplasm. Analysis of infected cells by fluorescence microscopy using antibodies against both the RSV and IAV nucleoproteins revealed that co-infection did not alter this localization – RSV was still in inclusion bodies and IAV was diffuse. The authors then analyzed later stages of infection, when in single infections, these viruses assemble in structures called lipid rafts in the plasma membrane. Their results using antibodies against the IAV hemagglutinin (HA) protein or the RSV F protein (i.e., the viral surface glycoproteins) revealed that in co-infections, both viruses were also simultaneously in the same region around the plasma membrane, suggesting that viral particles budding from the cell surface could contain components of both RSV and IAV.  

Using high resolution confocal microscopy and a technique known as cryo-electron tomography, which reconstructs a series of image slices to generate a three-dimensional structure of a sample, the authors found that co-infection of cells produced two types of particles. The first type, called ‘pseudotyped viruses,’ consisted of RSV particles with IAV glycoproteins. The second type, designated ‘hybrid virus particles’ (HVPs), were true hybrids containing the genomes and surface glycoproteins of both viruses with distinct structural regions characteristic of each virus. Because glycoproteins determine which cells and cell surface proteins viruses can bind to (i.e., their “antigenicity”), it is reasonable to assume that HVPs would have a modified antigenicity relative to IAV and RSV. IAV entry into cells occurs via the viral HA protein, which binds the cell surface protein sialic acid. RSV entry is effected in part via its F protein, which mediates fusion of the virus with the host cell membrane. To determine whether the HA and F glycoproteins on the HVPs were altered in terms of their antigenicity, the authors carried out a neutralization assay, which reveals whether an antibody can bind a glycoprotein and inactivate the viral particle. Anti-HA antibodies neutralized HVPs about three-fold less efficiently than viruses collected from cells that had only been infected with IAV, suggesting that the HA on HVPs is different enough so that antibodies won’t recognize it. In contrast, anti-F antibodies neutralized HVPs about as well as they did viruses isolated from cells infected with RSV only, suggesting that the antigenicity of the F glycoprotein on HVPs was well preserved. These results also suggested that HVPs cannot enter host cells using the IAV HA protein, and likely enters via the RSV F protein instead.    

To test this hypothesis, the authors treated cells with neuraminidase, which binds sialic acid and sequesters it, thus leaving no receptor for IAV to bind to and enter the cell. Viruses isolated from singly or co-infected cells were then used to infect these neuraminidase-treated cells, and the cells were stained with IAV and RSV nucleoprotein-specific fluorescent antibodies and visualized by fluorescence microscopy to determine whether IAV, RSV, or HVPs had infected them. As expected, neuraminidase-treated cells infected with viruses isolated from RSV only- or IAV only-infected cells contained RSV nucleoprotein but not IAV nucleoprotein, suggesting that IAV was unable to infect these cells (because there was no sialic acid to bind to), while RSV infected these cells normally because RSV entry is not dependent on sialic acid. Interestingly, neuraminidase-treated cells infected with viruses isolated from co-infected cells contained an abundance of IAV nucleoproteins, further implying that HVPs containing IAV genomes entered these cells using RSV F protein.

To confirm that the RSV F protein mediated HVP entry into cells, viruses isolated from co-infected cells were treated with a monoclonal antibody against RSV F protein before they were used to infect neuraminidase-treated cells. The monoclonal antibody would presumably sequester any viruses having the F protein and prevent any F protein-mediated entry into cells. This treatment led to significantly reduced entry of HVPs into cells, confirming that the RSV F protein mediates entry of hybrid particles into cells.

Studies of virus-host interactions are extremely common, and scientists have made a lot of progress in understanding the mechanisms that drive these interactions. In stark contrast, we know very little about how viruses interact with each other. Some work has shown that not all co-infections are successful and often result in “competitive exclusion,” with one virus displacing the other, thereby preventing it from completing a replication cycle or establishing an infection in the first place. To my knowledge, this is the first study showing that two completely different viruses can coordinate their replication cycles to develop some kind of symbiosis in a clear display of co-evolution. And although this phenomenon may seem extraordinary, it is probably more common than we think.  

[For a more detailed discussion of this study, please check out TWiV 958.]

Filed Under: Basic virology, Gertrud Rey Tagged With: antigenicity, co-infection, HA, hemagglutinin, hybrid virus, hybrid virus particle, IAV, influenza A, neuraminidase, rsv, RSV F protein, sialic acid, virus-virus interaction

TWiV 396: Influenza viruses with Peter Palese

3 July 2016 by Vincent Racaniello

TWiVVincent speaks with Peter Palese about his illustrious career in virology, from early work on neuraminidases to universal influenza virus vaccines, on episode #396 of the science show This Week in Virology.

You can find TWiV #396 at microbe.tv/twiv, or listen below.

[powerpress url=”http://traffic.libsyn.com/twiv/TWiV396.mp3″]

Click arrow to play
Download TWiV 396 (54 MB .mp3, 74 min)
Subscribe (free): iTunes, RSS, email

Filed Under: This Week in Virology Tagged With: aerosol transmission, ferret, Flu, gain of function, H5N1, influenza, influenza virus, neuraminidase, relenza, swine flu, tamiflu, universal vaccine, vaccine, viral, virology, virus, viruses

Cutting through mucus with the influenza virus neuraminidase

8 January 2014 by Vincent Racaniello

influenza virusNeuraminidase is one of three different viral proteins embedded in the lipid membrane of influenza virus (NA is blue in the illustration at left). This enzyme has a clear and proven role in virus release from cells. NA is also believed to be important during virus entry, by degrading the mucus barrier of the respiratory tract and allowing virus to reach cells. This role is supported by the finding that treatment of mucus-covered human airway epithelial cells with the NA inhibitor Tamiflu substantially suppresses the initiation of infection.  Further evidence comes from the recent finding that influenza virus binds to sialic acids in mucus and that NA cleaves these sugars to allow infection.

The mucus layer of the respiratory tract has a defensive role because it contains soluble glycoproteins that are rich in sialic acids, which are cell receptors for some viruses. When influenza virions enter the respiratory tract, they are thought to be trapped in mucus where they bind sialic acids, preventing infection of the underlying cells. The role of NA in penetration of the mucus layer was studied in frozen sections of human tracheal and bronchial tissues, in which the mucus layer is preserved. Influenza A virions bind to this mucus layer; the interaction is blocked when the tissues are first treated with a bacterial neuramindase, which removes sialic acids from glycoproteins. These observations indicate that the mucus layer of human airway epithelial cells contain sialic acid-containing decoys that bind influenza A viruses.

Human salivary mucins, which approximate the mucus of the human respiratory tract, can protect cultured cells from influenza virus infection. The protective effect can be achieved by simply adding the mucins to cells. The inhibitory effect is dependent on the sialic acid content of the mucins: fewer cells are infected when higher concentrations are used. In contrast, porcine salivary mucins do not substantially reduce influenza virus infection. The type of sialic acids and the virus strain also determine the extent of protection.

To determine the role of the viral NA in mucin-mediated inhibition, Tamiflu was mixed with virus before infection of mucus-coated cells. The presence of Tamiflu increased the inhibition of infection caused by mucins, indicating that the sialic acid-cleaving (sialidase) activity of NA is needed to overcome inhibition by human salivary mucins. When influenza virions are incubated with human salivary mucins linked to beads, sialic acids are cleaved from mucins, and this enzymatic activity is inhibited by Tamiflu. Human salivary mucins inhibit NA by binding to the active site of the enzyme.

These studies establish a clear role for the influenza viral NA in bypassing the defenses of the mucosal barrier. An important message is that not all strains of influenza virus are equally inhibited by mucus; presumably this property is one of many that determines viral virulence. The balance between how tightly the viral HA binds to sialic acids, and how well the NA cleaves them, is probably one predictor of how well we our protected by our mucus.

 

Filed Under: Basic virology, Information Tagged With: influenza, mucus, NA, neuraminidase, oseltamivir, tamiflu, viral, virology, virus

Changing influenza virus neuraminidase into a receptor binding protein

21 November 2013 by Vincent Racaniello

neuraminidaseThe hemagglutinin (HA) and neuraminidase (NA) glycoproteins of the influenza virus particle serve distinct functions during infection. The HA binds sialic acid-containing cellular receptors and mediates fusion of the viral and cell membranes, while the NA removes sialic acids from glycoproteins. Apparently this division of labor is not absolute: influenza viruses have been identified with NA molecules that serve as receptor binding proteins.

An influenza virus was created that could not bind sialic acid by introducing multiple mutations into the HA gene. This mutant virus was not expected to be infectious, but nevertheless did propagate to moderate titers in cell culture. A single amino acid change was identified in the NA protein of this virus: G147R, which is just above the active site of the enzyme (illustrated; active site marked with green spheres). Passage of the virus in cell culture produced a virus that multiplied to higher titers; improved growth was caused by a K62E change in the HA stalk. The results of site-directed mutagenesis showed that the G147R change allowed the NA protein to serve the receptor binding function normally provided by HA. It is not clear how the HA change leads to improved growth of the G147 virus.

Although the G147R NA can serve as receptor binding protein, the HA is still required for fusion: abolishing this activity by mutation or by treatment with a fusion-blocking antibody did not allow virus growth.

The influenza NA protein is an enzyme (sialidase) that cleaves sialic acids from cellular and viral proteins. The G147R NA is active as a sialidase, and this activity can be blocked by the antiviral compound oseltamivir, which is an NA inhibitor. Treatment of G147R-containing virus with oseltamivir also blocked virus binding to cells. Virus-like particles that contain G147R NA but not HA can attach to sialic acid-containing red blood cells. This attachment can be reversed by oseltamivir. After binding to red blood cells, these virus-like particles slowly fall off, a consequence of NA cleaving sialic acid receptors. These observations indicate that the G147R NA binds to sialic acids at the active site of the enzyme, and cleaves the same receptor that it binds.

Treatment of cells with a bacterial sialidase that removes a broad range of sialic acids only partially inhibits G147R NA-mediated binding to cells. In contrast, growth of wild type influenza virus is completely blocked by this treatment. Therefore the receptor recognized by G147R NA is not the same as that bound by wild type virus.

Changing the influenza virus NA to a receptor binding protein is not simply a laboratory curiosity: the G147R NA change was found in 31 of 19,528 NA protein sequences in the Influenza Virus Resource. They occur in seasonal H1N1 viruses that circulated before 2009, in the 2009 swine-origin pandemic H1N1 virus, and in avian H5N1 viruses. The presence of this change in phylogenetic clusters of seasonal H1N1 and chicken H5N1 sequences suggests that they are also found in circulating viruses, and are not simply sequence errors or the product of passage in the laboratory.

These observations emphasize the remarkable flexibility of the influenza viral glycoproteins in their ability to switch receptor binding function from HA to NA. They might also have implications for vaccines, whose effectiveness are thought to depend largely on the induction of antibodies that block the function of HA protein. The work underscores the importance of serendipity in science: the HA receptor binding mutant virus was originally produced as a negative control for a different experiment.

Filed Under: Basic virology, Information Tagged With: evolution, HA, hemagglutinin, influenza, mutation, NA, neuraminidase, receptor binding, sialidase, tamiflu, viral, virology, virus

The neuraminidase of influenza virus

5 November 2013 by Vincent Racaniello

influenza virusThe influenza virus particle is made up of the viral RNA genome wrapped in a lipid membrane (illustrated). The membrane, or envelope, contains three different kinds of viral proteins. The hemagglutinin molecule (HA, blue) attaches to cell receptors and initiates the process of virus entry into cells. I have written about the HA and its function during infection (article one and two) but not about the neuraminidase (NA, red) or M2 (purple) proteins. Let’s first tackle NA.

An important function of the NA protein is to remove sialic acid from glycoproteins. Sialic acid is present on many cell surface proteins as well as on the viral glycoproteins; it is the cell receptor to which influenza virus attaches via the HA protein. The sialic acids on the HA and NA are removed as the proteins move to the cell surface through the secretory pathway. Newly released virus particles can still potentially aggregate by binding of an HA to sialic acid present on the cell surface. Years ago Peter Palese showed that influenza virus forms aggregates at the cell surface when the viral neuraminidase is inactivated. The NA is therefore an enzyme that is essential for release of progeny virus particles from the surface of an infected cell.

The NA protein also functions during entry of virus into the respiratory tract. The epithelial cells of the respiratory tract are bathed in mucus, a complex protective coating that contains many sialic acid-containing glycoproteins. When influenza virions enter the respiratory tract, they are trapped in mucus where they bind sialic acids. This interaction would prevent the viruses from binding to a susceptible cell were it not for the action of the NA protein which cleaves sialic acids from glycoproteins. When the virus particle encounters a cell, it binds the sialic acid-containing receptor and is rapidly taken into the cell before the NA protein can cleave the carbohydrate from the cell surface.

The essential nature of the NA for virus production has been exploited to develop new drugs designed to inhibit viral release. Both Tamiflu (Oseltamivir) and Relenza (Zanamivir) are structural mimics of sialic acid that bind tightly in the active site of the NA enzyme. When bound to drug, the NA cannot remove sialic acids from the cell surface, and consequently newly synthesized virus remains immobilized. The result is an inhibition of virus infection because virions cannot spread from one cell to another.

This article is part of Influenza 101, a series of posts about influenza virus biology and pathogenesis.

Filed Under: Basic virology, Information Tagged With: glycoprotein, influenza, neuraminidase, relenza, sialic acid, spread, tamiflu, viral, virology, virus

TWiV 236: Flu gets the VIP treatment

9 June 2013 by Vincent Racaniello

On epside #236 of the science show This Week in Virology, Vincent, Alan and Kathy review novel approaches to preventing influenza virus infection.

You can find TWiV #236 at www.microbe.tv/twiv.

Filed Under: This Week in Virology Tagged With: aav, adeno-associated virus, broadly neutralizing antibody, codon pair bias, ferret, HA, hemagglutinin, influenza, mouse, NA, neuraminidase, vaccine, vector, vectored immunoprophylaxis, viral, virology, virus

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

by Vincent Racaniello

Earth’s virology Professor
Questions? virology@virology.ws

With David Tuller and
Gertrud U. Rey

Follow

Facebook, Twitter, YouTube, Instagram
Get updates by RSS or Email

Contents

Table of Contents
ME/CFS
Inside a BSL-4
The Wall of Polio
Microbe Art
Interviews With Virologists

Earth’s Virology Course

Virology Live
Columbia U
Virologia en Español
Virology 101
Influenza 101

Podcasts

This Week in Virology
This Week in Microbiology
This Week in Parasitism
This Week in Evolution
Immune
This Week in Neuroscience
All at MicrobeTV

Useful Resources

Lecturio Online Courses
HealthMap
Polio eradication
Promed-Mail
Small Things Considered
ViralZone
Virus Particle Explorer
The Living River
Parasites Without Borders

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.